Latest Radboud University Nijmegen Stories
NIJMEGEN, Netherlands, Oct. 15, 2012 /PRNewswire/ - The first of three newly acquired Elekta Synergy® treatment systems equipped with Agility(TM)* 160-leaf multi-leaf collimator (MLC) is now up and running clinically at Radboud University Nijmegen Medical Center - making the clinic the first in the Netherlands to use Agility. The first patient, a 48-year-old woman, was treated on September 10 and clinicians have treated 70 additional patients since then, encompassing a wide range...
PHILADELPHIA and LONDON, Feb. 15, 2012 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters today announced a two-year agreement with Radboud University Nijmegen, Netherlands, to provide access to the InCites(TM) platform, a customized, web-based research evaluation tool. The institutional performance analysis and benchmarking tools available through InCites will help the university measure the effectiveness of its research and compare it with peer...
Will our next generation of space travel be powered by cat urine? Researchers from Radboud University Nijmegen in the Netherlands released a study which details the work of a particular bacterium that turns the smelly contents of your cat box (or any other type of urine) into space fuel, AFP is reporting. The results of the scientists’ work show that the bacterium anammox, first identified in the 1990’s, thrives in the absence of oxygen and transforms ammonium, the ingredient of...
LEIDEN, The Netherlands, March 11, 2011 /PRNewswire/ -- Technology has been developed within Top Institute Pharma that helps medicines be absorbed quicker into the blood and thus be more effective. Researcher Hans de Waard, who is associated with the University of Groningen, will obtain his doctorate on this subject on March 11. De Waard: "Many current medicines are not easily dissolved in the digestive tract, which means that they barely reach the bloodstream. This, in turn, means that...
BILTHOVEN and NIJMEGEN, The Netherlands, April 22 /PRNewswire/ -- InteRNA Technologies B.V. and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for prostate cancer. Under the research collaboration with professor Jack Schalken (Laboratory of Experimental Urology), InteRNA's unique lentiviral-based miRNA overexpression library will be applied in multi-parametric, high-throughput functional screening...
